Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib

Steffan T. Nawrocki; Claudia M. Espitia; Maria Janina Carrera Espinoza; Trace M. Jones; Madison E. Gamble; Sruthi Sureshkumar; Mengyang Chang; Wei Wang; Jennifer S. Carew

doi:10.1002/ctm2.1662

Clinical and Translational Medicine ›› 2024, Vol. 14 ›› Issue (4) : e1662 DOI: 10.1002/ctm2.1662

LETTER TO THE JOURNAL

Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib

Author information +

History +

PDF

Cite this article

Download citation ▾

Steffan T. Nawrocki, Claudia M. Espitia, Maria Janina Carrera Espinoza, Trace M. Jones, Madison E. Gamble, Sruthi Sureshkumar, Mengyang Chang, Wei Wang, Jennifer S. Carew. Inhibition of autophagy antagonizes breast cancer brain metastogenesis and augments the anticancer activity of lapatinib. Clinical and Translational Medicine, 2024, 14(4): e1662 DOI:10.1002/ctm2.1662

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Patel RR, Mehta MP. Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res. 2007;13(6):1675-1683.

[2]	Jones TM, Carew JS, Nawrocki ST. Therapeutic targeting of autophagy for renal cell carcinoma therapy. Cancers. 2020;12(5):1185.

[3]	Nawrocki ST, Han Y, Visconte V, et al. The novel autophagy inhibitor ROC-325 augments the antileukemic activity of azacitidine. Leukemia. 2019;33(12):2971-2974.

[4]	Degenhardt K, Mathew R, Beaudoin B, et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell. 2006;10(1):51-64.

[5]	Gril B, Palmieri D, Bronder JL, et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J Natl Cancer Inst. 2008;100(15):1092-1103.

[6]	Liu H, Kato Y, Erzinger SA, et al. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer. 2012;12:583.

[7]	Palmieri D, Bronder JL, Herring JM, et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. Cancer Res. 2007;67(9):4190-4198.

[8]	Bartman CR, Weilandt DR, Shen Y, et al. Slow TCA flux and ATP production in primary solid tumours but not metastases. Nature. 2023;614(7947):349-357.

[9]	Lin NU, Dieras V, Paul D, et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009;15(4):1452-1459.

[10]

Lin NU, Guo H, Yap JT, et al. Phase II study of lapatinib in combination with trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: clinical outcomes and predictive value of early [18F]fluorodeoxyglucose positron emission tomography imaging (TBCRC 003). J Clin Oncol. 2015;33(24):2623-2631.

RIGHTS & PERMISSIONS

2024 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.